EADO Congress 2015

Dr Lorigan talks to ecancertv at EADO 2015 about the new challenges in drug combination and strategies and how to retreat melanoma patients who have progressed and are resistant to targeted therapies.

Dr Lorigan talks to ecancertv at EADO 2015 about the management of acute metastatic melanoma, and how best to approach patients who are very ill.

Dr Ascierto talks to ecancertv at EADO 2015 about the relationship between PD-L1 expression and antitumour activity in the KEYNOTE-002 study of pembrolizumab (MK-3475) vs chemotherapy for ipilimumab-refractory (IPI-R) advanced melanoma.

Prof Flaherty talks to ecancertv at EADO 2015 about the progress in targeted therapy of melanoma, and the advance in multi-target therapies.

Dr Harrington talks to ecancertv at EADO 2015 about the benefit and risk analysis from the phase III OPTiM trial of talimogene laherparepvec (T-VEC) vs granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with stage IIIB-IV melanoma.

Prof Zalaudek talks to ecancertv at EADO 2015 about why screening for melanoma is important. Early detection is still the most powerful method for preventing deaths from melanoma and non-melanoma skin cancers. She also discusses her "Think-Blink-Pink" screening process.

Prof Bishop talks to ecancertv at EADO 2015 about the use of supplements in order to get sufficient vitamin D to the body, rather than sunlight due to the melanoma risks. She also discusses the simple steps and guidelines for protection against the sun.

Prof Schadendorf talks to ecancertv at EADO 2015 about patient-reported outcomes (PROs) from the KEYNOTE-002 study of pembrolizumab (MK-3475) vs chemotherapy for ipilimumab-re- fractory (IPI-R) metastatic melanoma.

Prof Olive talks to ecancertv at EADO 2015 about how higher expression of HVEM by melanoma metastasis is associated with a significantly poorer survival from the date of excision. High levels of HVEM expression on melanoma may dampen anti-tumour immune responses, suggesting that together with its ligands, HVEM constitutes promising targets for antibody-mediated “checkpoint blockade” therapy.

Prof Hauschild talks to ecancertv at EADO 2015 about how talimogene laherparepvec (T-VEC) can be used early in melanoma treatment, leaving immunotherapy and targeted therapies for further treatment later. Prof Hauschild also discusses the new licence for the adjuvant use of ipilimumab. He states that it is highly questionable because of high toxicity and extremely high cost.

Prof Hauschild talks to ecancertv at EADO 2015 about how his study shows that mutated N-RAS is an independent new pathway for targeting.

Prof Hauschild talks to ecancertv at EADO 2015 about how this open label study shows there is a survival “tail”. Vemurafenib is an oral, selective inhibitor of activated BRAF that has shown high response rates and improved progression-free survival and overall survival in patients with BRAFV600 mutation–positive melanoma.

Prof Saiag talks to ecancertv at EADO 2015 about the prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients.

Prof Saiag talks to ecancertv at EADO 2015 about the prognostic value of BRAFV600 mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort.

Dr Middleton talks to ecancertv at EADO 2015 about combining immunotherapies and targeted therapies in melanoma. Should we be using anti-PD1 or tyrosine kinase inhibitors to treat patients?

Prof Grob talks to ecancertv about the highlights of EADO 2015. He discusses exciting emerging topics in melanoma, progression of individualising patient treatment and prognosis of skin cancer.

Prof Grob talks to ecancertv at EADO 2015 about the clinical findings of nivolumab and ipilimumab in combination.

Prof McArthur talks to ecancertv at EADO 2015 about combination approaches of immune based therapies and targeted therapies in melanoma. He describes these treatments as "disruptive technologies" in cancer due to how the development in technology is affecting survivorship and giving durable, long-lasting responses. In short, there are workforce issues associated with this in some clinics, due to patients living longer.

Prof McArthur talks to ecancertv at EADO 2015 about the latest from the CoBRIM study. This study looks into predictive and prognostic targets to refine subgroups in melanoma.

Prof Long talks to ecancertv at EADO 2015 about her role as a "Melanoma-ologist" and the progress that is being made in the targeted therapy of melanoma.

Prof Garbe talks to ecancertv at EADO 2015 about how and when to combine immunotherapy and targeted therapies to treat melanoma. Should we use Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Dreno talks to ecancertv at EADO 2015 about the Co-BRIM study. This study looks at health-related quality-of-life assessment in patients with metastatic melanoma receiving vemurafenib cobimetinib.

Dr Viros talks to ecancertv at EADO 2015 about the real role of UV in melanoma, and the environmental risk factors associated with melanoma and non-melanoma skin cancer.